Skip to main content
Biodefense Market Analysis Asia, North America, Europe, Rest of World (ROW) - US, UK, Germany, China, India - Size and Forecast 2024-2028

Biodefense Market Analysis Asia, North America, Europe, Rest of World (ROW) - US, UK, Germany, China, India - Size and Forecast 2024-2028

Published: Feb 2024 166 Pages SKU: IRTNTR43768

Market Overview at a Glance

$7.16 B
Market Opportunity
-4.96%
CAGR
-13.22
YoY growth 2023-2024(%)

Biodefense Market Size 2024-2028 

The biodefense market size is forecast to decrease by USD 7.16 billion at a CAGR of 4.96% between 2023 and 2028. The market is experiencing significant growth due to the increasing threat posed by hazardous biological agents and the need for preventative steps in industrialized nations. The market is witnessing a rise in product launches and strategic alliances among key players, with a focus on developing advanced bio-threat-detecting tools, nanotechnology, gene chips, and plasmid DNA constructions for the detection of infections and drug development. The lack of information about bioengineered organisms attacks presents a challenge, necessitating the development of sophisticated biodefense systems. The healthcare infrastructure in various countries is undergoing transformation to accommodate the demands of biomedical innovation and the production of stocks of vaccines and treatments. The market's future growth is expected to be driven by the continued efforts to enhance human health and safeguard against biothreats.

Biodefense Market Size

 Request Free Sample

The market encompasses the production and distribution of medical measures and military measures to counteract biological threats. These threats include anthrax spores, botulism, and various infectious agents such as bacteria and viruses, as well as biological toxins, chemical agents, and radioactive agents. Biodefense is crucial in preventing the use of biological weapons, which can be engineered through genetic engineering and biotechnology to create new and deadly organisms. Anthrax, for instance, is a significant concern due to its potential use as a weapon, and medical countermeasures are essential to mitigate its effects. Biosecurity measures are also vital in safeguarding against biological threats, whether they originate from natural sources or intentional releases. The market for biodefense continues to grow as the threat landscape evolves and new technologies emerge to address these challenges.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

  • Type
    • Vaccines
    • Drugs
  • Application
    • COVID 19
    • Anthrax
    • Smallpox
    • Botulism
    • Others
  • Geography
    • Asia
      • China
      • India
    • North America
      • US
    • Europe
      • Germany
      • UK
    • Rest of World (ROW)

By Type Insights

The vaccines segment is estimated to witness significant growth during the forecast period. Biodefense vaccines play a crucial role in safeguarding populations against intentional biological attacks, emerging infectious diseases, and bioterrorism incidents. These vaccines are engineered to prevent the dissemination of pathogens that could be employed in deliberate attacks or emerge naturally. Several biodefense vaccines have been engineered and authorized for use in various nations, serving as indispensable resources in national preparedness and response strategies. For instance, Emergent BioSolutions' anthrax vaccine adsorbed (AVA) is one of the primary vaccines utilized to shield against anthrax, a bacterial agent that can be weaponized for bioterrorism. AVA has been granted approval by regulatory authorities in the United States and other countries and is maintained in stockpiles for use during anthrax attacks.

Furthermore, biodefense vaccines are also essential in mitigating economic losses caused by fatal viruses such as Zika, Flu, Ebola, and other diseases. Furthermore, biodefense vaccines are instrumental in protecting against chemical and nuclear agents, as well as biological threats from smallpox, botulism, and other hazardous organisms. In the face of increasing biological, chemical, radiological, and nuclear threats, utilizing medical countermeasures, including vaccines, is essential for effective response and prevention strategies.

Biodefense Market Size

Get a glance at the market share of various segments Request Free Sample

The vaccines segment was valued at USD 8.21 billion in 2018 and showed a gradual increase during the forecast period.

Regional Insights

Rest of World (ROW) is estimated to contribute 11% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Biodefense Market Share by Geography

For more insights on the market share of various regions Request Free Sample

The region is projected to witness the fastest growth in the market due to the rising threat of bioterrorism. Biological threats, including fatal viruses such as Zika, Flu, and Ebola, pose significant risks, particularly in regions with low research capabilities. Additionally, the possibility of chemical, nuclear, and radiological agent attacks is a major concern. The devastating consequences of such incidents, both in terms of human lives and economic loss, necessitate the utilization of medical countermeasures. The potential for bioterrorism in a region that comprises over half of the world's population could have catastrophic effects. Notable examples include the Smallpox virus and Botulism toxin. In light of these concerns, governments and organizations are investing heavily in biodefense research and development to mitigate these threats.

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Market Driver

Increasing threat posed by biological agents is the key driver of the market. The market has experienced significant growth due to the increasing threat of biological agents, including anthrax spores from Bacillus anthracis, as well as viruses, fungi, and toxins. Anthrax vaccines from companies like Emergent Bioscience play a crucial role in medical and military measures against this bacterial disease. The need for biodefense measures has been underscored by recent events such as the Ebola virus outbreak, the Zika virus epidemic, and the ongoing COVID-19 pandemic.

Furthermore, these incidents have highlighted the devastating impact of infectious diseases and the importance of strengthening preparedness and response capabilities. The threat landscape continues to evolve, with emerging infectious agents, drug-resistant pathogens, and the potential for engineered bioweapons posing new challenges to biosecurity. Biological toxins and infectious agents, whether naturally occurring or engineered, can cause significant harm and require effective countermeasures. Biological warfare, whether intentional or accidental, can have catastrophic consequences, making strong biodefense measures essential for protecting populations and critical infrastructure.

Market Trends

Rising product launches and strategic alliances among market participants is the upcoming trend in the market. The market is witnessing significant growth due to the increasing threats from anthrax spores and other infectious agents, including bacteria, viruses, fungi, and toxins.

Furthermore, biological warfare and biosecurity concerns have heightened the demand for medical measures and military measures to combat these threats. companies in the market are responding with strategic alliances, such as partnerships, mergers and acquisitions (M&A), and new product launches. These strategic moves will help companies expand their product offerings and strengthen their market position.

Market Challenge

Lack of information about bioengineered organism attacks is a key challenge affecting market growth. The market encompasses various medical and military measures aimed at preventing, detecting, and responding to threats posed by infectious agents, biological toxins, and genetically altered organisms. These threats can include naturally occurring diseases such as Anthrax caused by Bacillus anthracis spores, as well as potential biological warfare agents and other companies have developed Anthrax vaccines to mitigate the risks associated with this bacterium.

However, the use of genetically modified organisms in scientific research and potential malicious applications poses significant challenges to the market. The unique properties of these organisms and the clinical symptoms displayed by infected individuals may surpass conventional diagnostic and preventive measures. The potential for creating new pathogens or biological threat agents with exclusive properties is a major concern for biosecurity and public health. The market is, therefore, essential in addressing these challenges and ensuring the development of effective countermeasures against a wide range of biological threats.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Biodefense Market Share by Geography

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Alnylam Pharmaceuticals Inc. -The company offers biodefense solution such as RNAi therapeutics for the treatment of amyloidosis, hyperoxaluria, and porphyria.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

  • Appili Therapeutics Inc.
  • AstraZeneca PLC
  • Bavarian Nordic AS
  • Chimerix Inc.
  • Dynavax Technologies Corp.
  • Elusys Therapeutics Inc.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Neogen Corp.
  • Novavax Inc.
  • Porton Biopharma Ltd.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • SIGA Technologies Inc.
  • Soligenix Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Zoetis Inc.
  • Johnson and Johnson

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

The market encompasses medical measures and military strategies aimed at mitigating threats posed by infectious agents, biological toxins, bacteria, viruses, fungi, and chemical & nuclear agents. These threats include anthrax spores, anthrax (Bacillus anthracis), smallpox, botulism, radiological threats, and nuclear threats, among others. The market is driven by the need to develop vaccines and medical countermeasures against fatal viruses such as Ebola, Zika, flu, and viral hemorrhagic fever, as well as bacterial diseases like brucellosis, cholera, and plague. Biodefense initiatives also focus on the detection and prevention of biothreat agents, including food poisoning, tularemia, and ebola. Scientific advancements in biotechnology, genetic engineering, and nanotechnology play a crucial role in the development of sophisticated biodefense systems.

Furthermore, biodefense laws and support from governments, public health services, and industrialized nations have led to efforts in vaccine development, clinical trials, and the creation of stocks of vaccines and bio-threat-detecting tools. The market also includes the development of technologically sophisticated products, such as detectors/triggering devices, samplers, reagents, and identifiers, for the detection of infections and the production of vaccines using novel vaccination technologies like vector technology and oral doses. The immune response to bioterrorism agents and threats is a key focus of biodefense initiatives, with efforts to develop hyperimmune development programs, plasma-derived therapy, and preventative steps to minimize economic loss from bio-incidents.

Market Scope

Report Coverage

Details

Page number

166

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Decelerate at a CAGR of 4.96%

Market growth 2024-2028

USD -7.16 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

-13.22

Regional analysis

Asia, North America, Europe, and Rest of World (ROW)

Performing market contribution

Rest of World (ROW) at 11%

Key countries

US, UK, Germany, China, and India

Competitive landscape

Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Alnylam Pharmaceuticals Inc., Appili Therapeutics Inc., AstraZeneca PLC, Bavarian Nordic AS, Chimerix Inc., Dynavax Technologies Corp., Elusys Therapeutics Inc., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Merck and Co. Inc., Neogen Corp., Novavax Inc., Porton Biopharma Ltd., Sanofi SA, Serum Institute of India Pvt. Ltd., SIGA Technologies Inc., Soligenix Inc., Tonix Pharmaceuticals Holding Corp., Zoetis Inc., and Johnson and Johnson

Market dynamics

Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period

Customization purview

If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
  • Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
  • Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
  • Growth of the market across Asia, North America, Europe, and Rest of World (ROW)
  • Thorough analysis of the market's competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global biodefense market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global biodefense market 2018 - 2022 ($ million)
    • 4.2 Type Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ million)
    • 4.3 Application Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Application Segment 2018 - 2022 ($ million)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Type

    • 6.1 Market segments
      • Exhibit 30: Chart on Type - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
    • 6.2 Comparison by Type
      • Exhibit 32: Chart on Comparison by Type
      • Exhibit 33: Data Table on Comparison by Type
    • 6.3 Vaccines - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Vaccines - Market size and forecast 2023-2028 ($ million)
      • Exhibit 35: Data Table on Vaccines - Market size and forecast 2023-2028 ($ million)
      • Exhibit 36: Chart on Vaccines - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Vaccines - Year-over-year growth 2023-2028 (%)
    • 6.4 Drugs - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Drugs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 39: Data Table on Drugs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 40: Chart on Drugs - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Drugs - Year-over-year growth 2023-2028 (%)
    • 6.5 Market opportunity by Type
      • Exhibit 42: Market opportunity by Type ($ million)
      • Exhibit 43: Data Table on Market opportunity by Type ($ million)

    7 Market Segmentation by Application

    • 7.1 Market segments
      • Exhibit 44: Chart on Application - Market share 2023-2028 (%)
      • Exhibit 45: Data Table on Application - Market share 2023-2028 (%)
    • 7.2 Comparison by Application
      • Exhibit 46: Chart on Comparison by Application
      • Exhibit 47: Data Table on Comparison by Application
    • 7.3 COVID 19 - Market size and forecast 2023-2028
      • Exhibit 48: Chart on COVID 19 - Market size and forecast 2023-2028 ($ million)
      • Exhibit 49: Data Table on COVID 19 - Market size and forecast 2023-2028 ($ million)
      • Exhibit 50: Chart on COVID 19 - Year-over-year growth 2023-2028 (%)
      • Exhibit 51: Data Table on COVID 19 - Year-over-year growth 2023-2028 (%)
    • 7.4 Anthrax - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Anthrax - Market size and forecast 2023-2028 ($ million)
      • Exhibit 53: Data Table on Anthrax - Market size and forecast 2023-2028 ($ million)
      • Exhibit 54: Chart on Anthrax - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Anthrax - Year-over-year growth 2023-2028 (%)
    • 7.5 Smallpox - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Smallpox - Market size and forecast 2023-2028 ($ million)
      • Exhibit 57: Data Table on Smallpox - Market size and forecast 2023-2028 ($ million)
      • Exhibit 58: Chart on Smallpox - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Smallpox - Year-over-year growth 2023-2028 (%)
    • 7.6 Botulism - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Botulism - Market size and forecast 2023-2028 ($ million)
      • Exhibit 61: Data Table on Botulism - Market size and forecast 2023-2028 ($ million)
      • Exhibit 62: Chart on Botulism - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Botulism - Year-over-year growth 2023-2028 (%)
    • 7.7 Others - Market size and forecast 2023-2028
      • Exhibit 64: Chart on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 65: Data Table on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 66: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 67: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 7.8 Market opportunity by Application
      • Exhibit 68: Market opportunity by Application ($ million)
      • Exhibit 69: Data Table on Market opportunity by Application ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 71: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 72: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 73: Chart on Geographic comparison
      • Exhibit 74: Data Table on Geographic comparison
    • 9.3 Asia - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.4 North America - Market size and forecast 2023-2028
      • Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.5 Europe - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 China - Market size and forecast 2023-2028
      • Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.9 India - Market size and forecast 2023-2028
      • Exhibit 99: Chart on India - Market size and forecast 2023-2028 ($ million)
      • Exhibit 100: Data Table on India - Market size and forecast 2023-2028 ($ million)
      • Exhibit 101: Chart on India - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on India - Year-over-year growth 2023-2028 (%)
    • 9.10 UK - Market size and forecast 2023-2028
      • Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.11 Germany - Market size and forecast 2023-2028
      • Exhibit 107: Chart on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 108: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 109: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 110: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 111: Market opportunity by geography ($ million)
      • Exhibit 112: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 113: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 115: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 116: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 117: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 118: Matrix on vendor position and classification
            • 12.3 Alnylam Pharmaceuticals Inc.
              • Exhibit 119: Alnylam Pharmaceuticals Inc. - Overview
              • Exhibit 120: Alnylam Pharmaceuticals Inc. - Product / Service
              • Exhibit 121: Alnylam Pharmaceuticals Inc. - Key offerings
            • 12.4 Appili Therapeutics Inc.
              • Exhibit 122: Appili Therapeutics Inc. - Overview
              • Exhibit 123: Appili Therapeutics Inc. - Product / Service
              • Exhibit 124: Appili Therapeutics Inc. - Key offerings
            • 12.5 AstraZeneca PLC
              • Exhibit 125: AstraZeneca PLC - Overview
              • Exhibit 126: AstraZeneca PLC - Product / Service
              • Exhibit 127: AstraZeneca PLC - Key news
              • Exhibit 128: AstraZeneca PLC - Key offerings
            • 12.6 Bavarian Nordic AS
              • Exhibit 129: Bavarian Nordic AS - Overview
              • Exhibit 130: Bavarian Nordic AS - Product / Service
              • Exhibit 131: Bavarian Nordic AS - Key offerings
            • 12.7 Chimerix Inc.
              • Exhibit 132: Chimerix Inc. - Overview
              • Exhibit 133: Chimerix Inc. - Product / Service
              • Exhibit 134: Chimerix Inc. - Key offerings
            • 12.8 Dynavax Technologies Corp.
              • Exhibit 135: Dynavax Technologies Corp. - Overview
              • Exhibit 136: Dynavax Technologies Corp. - Product / Service
              • Exhibit 137: Dynavax Technologies Corp. - Key offerings
            • 12.9 Elusys Therapeutics Inc.
              • Exhibit 138: Elusys Therapeutics Inc. - Overview
              • Exhibit 139: Elusys Therapeutics Inc. - Product / Service
              • Exhibit 140: Elusys Therapeutics Inc. - Key offerings
            • 12.10 Emergent BioSolutions Inc.
              • Exhibit 141: Emergent BioSolutions Inc. - Overview
              • Exhibit 142: Emergent BioSolutions Inc. - Product / Service
              • Exhibit 143: Emergent BioSolutions Inc. - Key news
              • Exhibit 144: Emergent BioSolutions Inc. - Key offerings
            • 12.11 GlaxoSmithKline Plc
              • Exhibit 145: GlaxoSmithKline Plc - Overview
              • Exhibit 146: GlaxoSmithKline Plc - Business segments
              • Exhibit 147: GlaxoSmithKline Plc - Key news
              • Exhibit 148: GlaxoSmithKline Plc - Key offerings
              • Exhibit 149: GlaxoSmithKline Plc - Segment focus
            • 12.12 Johnson and Johnson
              • Exhibit 150: Johnson and Johnson - Overview
              • Exhibit 151: Johnson and Johnson - Business segments
              • Exhibit 152: Johnson and Johnson - Key news
              • Exhibit 153: Johnson and Johnson - Key offerings
              • Exhibit 154: Johnson and Johnson - Segment focus
            • 12.13 Novavax Inc.
              • Exhibit 155: Novavax Inc. - Overview
              • Exhibit 156: Novavax Inc. - Product / Service
              • Exhibit 157: Novavax Inc. - Key offerings
            • 12.14 Sanofi SA
              • Exhibit 158: Sanofi SA - Overview
              • Exhibit 159: Sanofi SA - Business segments
              • Exhibit 160: Sanofi SA - Key news
              • Exhibit 161: Sanofi SA - Key offerings
              • Exhibit 162: Sanofi SA - Segment focus
            • 12.15 SIGA Technologies Inc.
              • Exhibit 163: SIGA Technologies Inc. - Overview
              • Exhibit 164: SIGA Technologies Inc. - Product / Service
              • Exhibit 165: SIGA Technologies Inc. - Key offerings
            • 12.16 Soligenix Inc.
              • Exhibit 166: Soligenix Inc. - Overview
              • Exhibit 167: Soligenix Inc. - Business segments
              • Exhibit 168: Soligenix Inc. - Key offerings
              • Exhibit 169: Soligenix Inc. - Segment focus
            • 12.17 Tonix Pharmaceuticals Holding Corp.
              • Exhibit 170: Tonix Pharmaceuticals Holding Corp. - Overview
              • Exhibit 171: Tonix Pharmaceuticals Holding Corp. - Product / Service
              • Exhibit 172: Tonix Pharmaceuticals Holding Corp. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 173: Inclusions checklist
                • Exhibit 174: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 175: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 176: Research methodology
                • Exhibit 177: Validation techniques employed for market sizing
                • Exhibit 178: Information sources
              • 13.5 List of abbreviations
                • Exhibit 179: List of abbreviations

              Research Methodology

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              Interested in this report?

              Get your sample now to see our research methodology and insights!

              Download Now

              Frequently Asked Questions

              Biodefense market growth will increase by $ -7161.34 mn during 2024-2028 .

              The Biodefense market is expected to grow at a CAGR of -4.96% during 2024-2028 .

              Biodefense market is segmented by Type( Vaccines, Drugs, botulism, others) Application( COVID 19, Anthrax, Smallpox, Botulism, Others)

              Alnylam Pharmaceuticals Inc., Appili Therapeutics Inc., AstraZeneca PLC, Bavarian Nordic AS, Chimerix Inc., Dynavax Technologies Corp., Elusys Therapeutics Inc., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Merck and Co. Inc., Neogen Corp., Novavax Inc., Porton Biopharma Ltd., Sanofi SA, Serum Institute of India Pvt. Ltd., SIGA Technologies Inc., Soligenix Inc., Tonix Pharmaceuticals Holding Corp., Zoetis Inc., Johnson and Johnson are a few of the key vendors in the Biodefense market.

              Rest of World (ROW) will register the highest growth rate of 11% among the other regions. Therefore, the Biodefense market in Rest of World (ROW) is expected to garner significant business opportunities for the vendors during the forecast period.

              US, UK, Germany, China, India

              • Increasing threat posed by biological agentsIn recent years is the driving factor this market.
              • there has been a notable rise in the frequency and severity of infectious disease outbreaks is the driving factor this market.
              • pandemics is the driving factor this market.
              • and bioterrorism incidents worldwide. Events such as the Ebola virus outbreak in West Africa is the driving factor this market.
              • the Zika virus epidemic in the Americas is the driving factor this market.
              • and COVID-19 in 2020 have underscored the vulnerability of populations to biological threats and the critical need for robust biodefense measures. These incidents have heightened awareness among governments is the driving factor this market.
              • healthcare organizations is the driving factor this market.
              • and the public about the potential devastation caused by infectious diseases is the driving factor this market.
              • spurring efforts to enhance preparedness and response capabilities. Moreover is the driving factor this market.
              • the threat landscape is evolving is the driving factor this market.
              • with emerging infectious agents is the driving factor this market.
              • drug-resistant pathogens is the driving factor this market.
              • and the potential for engineered bioweapons posing new challenges. Advances in biotechnology and synthetic biology (genome editing) have made it easier to manipulate and weaponize pathogens is the driving factor this market.
              • increasing the risk of deliberate biological attacks. As a result is the driving factor this market.
              • governments and security agencies are prioritizing investments in biodefense technologies and capabilities to detect is the driving factor this market.
              • prevent is the driving factor this market.
              • and mitigate the impact of biological threats. Therefore is the driving factor this market.
              • the increasing threat posed by biological agents will drive the growth of the global biodefense market during the forecast period. is the driving factor this market.

              The Biodefense market vendors should focus on grabbing business opportunities from the Vaccines segment as it accounted for the largest market share in the base year.